Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1378689rdf:typepubmed:Citationlld:pubmed
pubmed-article:1378689lifeskim:mentionsumls-concept:C0007202lld:lifeskim
pubmed-article:1378689lifeskim:mentionsumls-concept:C0079594lld:lifeskim
pubmed-article:1378689lifeskim:mentionsumls-concept:C0184661lld:lifeskim
pubmed-article:1378689pubmed:dateCreated1992-8-20lld:pubmed
pubmed-article:1378689pubmed:abstractTextThe inhibition of platelet aggregation during cardiopulmonary bypass and effects on post-operative placebo-controlled study of 145 patients. Significant preservation of platelet numbers and function were shown without significant haemodynamic problems, but no effect on cerebral deficits could be found. The use of iloprost in patients with severe thrombocytopenia seems justified, but the clinical benefits from its use in routine cardiopulmonary bypass remain to be shown.lld:pubmed
pubmed-article:1378689pubmed:languageenglld:pubmed
pubmed-article:1378689pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1378689pubmed:citationSubsetIMlld:pubmed
pubmed-article:1378689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1378689pubmed:statusMEDLINElld:pubmed
pubmed-article:1378689pubmed:issn0379-0363lld:pubmed
pubmed-article:1378689pubmed:authorpubmed-author:BelcherGGlld:pubmed
pubmed-article:1378689pubmed:authorpubmed-author:DoleW PWPlld:pubmed
pubmed-article:1378689pubmed:authorpubmed-author:WatsonH RHRlld:pubmed
pubmed-article:1378689pubmed:authorpubmed-author:BrierleyJ KJKlld:pubmed
pubmed-article:1378689pubmed:issnTypePrintlld:pubmed
pubmed-article:1378689pubmed:volume37lld:pubmed
pubmed-article:1378689pubmed:ownerNLMlld:pubmed
pubmed-article:1378689pubmed:authorsCompleteYlld:pubmed
pubmed-article:1378689pubmed:pagination346-53lld:pubmed
pubmed-article:1378689pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:meshHeadingpubmed-meshheading:1378689-...lld:pubmed
pubmed-article:1378689pubmed:year1992lld:pubmed
pubmed-article:1378689pubmed:articleTitleIloprost in cardiopulmonary bypass procedures.lld:pubmed
pubmed-article:1378689pubmed:affiliationCardiovascular Clinical Research Unit, Schering Health Care, West Sussex, England.lld:pubmed
pubmed-article:1378689pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1378689pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1378689pubmed:publicationTypeRandomized Controlled Triallld:pubmed